3-Month Lag/Transition Period | 6-Month Lag/Transition Period | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention: Oxycontin ADF released (2010 Q3) | Intervention: Oxycontin ADF released (2010 Q3) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.36 | 0.002 | -183.1 | AR1 (𝜖) | 0.32 | 0.007 | -185.5 | ||||||||||
Intercept (𝛽0) | 0.27 | < 0.001 | Intercept (𝛽0) | 0.28 | < 0.001 | ||||||||||||
Time (𝛽1) | 0.02 | < 0.001 | Time (𝛽1) | 0.02 | < 0.001 | ||||||||||||
Ramp (𝛽2) | -0.03 | < 0.001 | Ramp (𝛽2) | -0.03 | < 0.001 | ||||||||||||
Intervention: Peak dosage units (2011 Q3) | Intervention: Peak dosage units (2011 Q3) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.25 | 0.042 | -189.2 | AR1 (𝜖) | 0.25 | 0.042 | -188.6 | ||||||||||
Intercept (𝛽0) | 0.31 | < 0.001 | Intercept (𝛽0) | 0.32 | < 0.001 | ||||||||||||
Time (𝛽1) | 0.01 | < 0.001 | Time (𝛽1) | 0.01 | < 0.001 | ||||||||||||
Ramp (𝛽2) | -0.03 | < 0.001 | Ramp (𝛽2) | -0.03 | < 0.001 | ||||||||||||
Intervention: Peak MMEs (2012 Q4) | Intervention: Peak MMEs (2012 Q4) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.38 | 0.001 | -181.6 | AR1 (𝜖) | 0.43 | < 0.001 | -178.3 | ||||||||||
Intercept (𝛽0) | 0.35 | < 0.001 | Intercept (𝛽0) | 0.36 | < 0.001 | ||||||||||||
Time (𝛽1) | 0.01 | < 0.001 | Time (𝛽1) | 0.01 | < 0.001 | ||||||||||||
Ramp (𝛽2) | -0.03 | < 0.001 | Ramp (𝛽2) | -0.03 | < 0.001 |